Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
This membrane protein is Human TNFR1 / CD120a / TNFRSF1A (22-211). It has been tested in SDS-PAGE, ELISA. We provide this protein to facilitate your membrane protein antibody discovery and development.
Product Specifications
Host Species
Human
Target Protein
TNFR1 / CD120a / TNFRSF1A
Protein Length
ECD
Molecular Weight
The protein has a calculated MW of 22.3 kDa. The protein migrates as 28-40 kDa under reducing (R) condition (SDS-PAGE) due to different glycosylation.
Sequence
AA Ile 22 - Thr 211 (Accession # NP_001056).
Product Description
Activity
Yes
Application
SDS-PAGE, ELISA
Expression Systems
HEK293
Tag
His tag at the C-terminus
Protein Format
Soluble
Reconstitution
Please see Certificate of Analysis for specific instructions.
Endotoxin
<1.0 EU/μg by the LAL method
Purity
>90% as determined by SDS-PAGE.
Buffer
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Target
Target Protein
TNFR1 / CD120a / TNFRSF1A
Full Name
TNF receptor superfamily member 1A
Introduction
This gene encodes a member of the TNF receptor superfamily of proteins. The encoded receptor is found in membrane-bound and soluble forms that interact with membrane-bound and soluble forms, respectively, of its ligand, tumor necrosis factor alpha. Binding of membrane-bound tumor necrosis factor alpha to the membrane-bound receptor induces receptor trimerization and activation, which plays a role in cell survival, apoptosis, and inflammation. Proteolytic processing of the encoded receptor results in release of the soluble form of the receptor, which can interact with free tumor necrosis factor alpha to inhibit inflammation. Mutations in this gene underlie tumor necrosis factor receptor-associated periodic syndrome (TRAPS), characterized by fever, abdominal pain and other features. Mutations in this gene may also be associated with multiple sclerosis in human patients.